JP2013527189A5 - - Google Patents

Download PDF

Info

Publication number
JP2013527189A5
JP2013527189A5 JP2013511686A JP2013511686A JP2013527189A5 JP 2013527189 A5 JP2013527189 A5 JP 2013527189A5 JP 2013511686 A JP2013511686 A JP 2013511686A JP 2013511686 A JP2013511686 A JP 2013511686A JP 2013527189 A5 JP2013527189 A5 JP 2013527189A5
Authority
JP
Japan
Prior art keywords
cresol
composition according
composition
antibody
phenol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013511686A
Other languages
English (en)
Japanese (ja)
Other versions
JP6294075B2 (ja
JP2013527189A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/058648 external-priority patent/WO2011147921A1/en
Publication of JP2013527189A publication Critical patent/JP2013527189A/ja
Publication of JP2013527189A5 publication Critical patent/JP2013527189A5/ja
Application granted granted Critical
Publication of JP6294075B2 publication Critical patent/JP6294075B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013511686A 2010-05-28 2011-05-26 抗体及び防腐剤を含む安定した多用量組成物 Active JP6294075B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10164298 2010-05-28
EP10164298.1 2010-05-28
US35152210P 2010-06-04 2010-06-04
US61/351,522 2010-06-04
PCT/EP2011/058648 WO2011147921A1 (en) 2010-05-28 2011-05-26 Stable multi-dose compositions comprising an antibody and a preservative

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016022657A Division JP6239657B2 (ja) 2010-05-28 2016-02-09 抗体及び防腐剤を含む安定した多用量組成物

Publications (3)

Publication Number Publication Date
JP2013527189A JP2013527189A (ja) 2013-06-27
JP2013527189A5 true JP2013527189A5 (OSRAM) 2014-07-03
JP6294075B2 JP6294075B2 (ja) 2018-03-14

Family

ID=42562357

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013511686A Active JP6294075B2 (ja) 2010-05-28 2011-05-26 抗体及び防腐剤を含む安定した多用量組成物
JP2016022657A Active JP6239657B2 (ja) 2010-05-28 2016-02-09 抗体及び防腐剤を含む安定した多用量組成物
JP2017211614A Active JP6568917B2 (ja) 2010-05-28 2017-11-01 抗体及び防腐剤を含む安定した多用量組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016022657A Active JP6239657B2 (ja) 2010-05-28 2016-02-09 抗体及び防腐剤を含む安定した多用量組成物
JP2017211614A Active JP6568917B2 (ja) 2010-05-28 2017-11-01 抗体及び防腐剤を含む安定した多用量組成物

Country Status (14)

Country Link
US (2) US20130136733A1 (OSRAM)
EP (1) EP2575761B1 (OSRAM)
JP (3) JP6294075B2 (OSRAM)
KR (1) KR20130086144A (OSRAM)
CN (2) CN102905692B (OSRAM)
AU (1) AU2011257219B2 (OSRAM)
BR (1) BR112012030139A2 (OSRAM)
CA (1) CA2800188A1 (OSRAM)
ES (1) ES2993022T3 (OSRAM)
HR (1) HRP20241526T1 (OSRAM)
MX (1) MX2012013586A (OSRAM)
RS (1) RS66182B1 (OSRAM)
RU (1) RU2012153786A (OSRAM)
WO (1) WO2011147921A1 (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1642983A (zh) 2002-01-25 2005-07-20 G2治疗有限公司 抗C5aR抗体及其应用
CN101970494B (zh) 2008-02-20 2015-01-21 G2炎症私人有限公司 人源化抗-C5aR抗体
JP2011526591A (ja) 2008-06-30 2011-10-13 ノボ・ノルデイスク・エー／エス 抗ヒトインターロイキン−２０抗体
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
BR112012021576A2 (pt) 2010-02-26 2016-10-25 Novo Nordisk As composições estáveis contendo anticorpo.
EA201892184A1 (ru) 2010-03-01 2019-03-29 БАЙЕР ХЕЛЬСКЕР ЛЛСи Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
US20130136733A1 (en) * 2010-05-28 2013-05-30 Novo Nordisk A/S Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
DK3424953T3 (en) 2011-06-06 2020-11-02 Novo Nordisk As Terapeutiske antistoffer
AU2013221635B2 (en) * 2012-02-16 2017-12-07 Santarus, Inc. Anti-VLA1 (CD49a) antibody pharmaceutical compositions
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
ES2702246T3 (es) * 2012-03-26 2019-02-28 Sanofi Sa Formulaciones de agente de unión IgG4 estables
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
WO2014015133A1 (en) 2012-07-19 2014-01-23 National Cheng Kung University Treatment of osteoarthritis using il-20 antagonists
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
TWI694836B (zh) 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
AU2016307967C9 (en) 2015-08-19 2025-02-20 Pfizer Inc. Tissue factor pathway inhibitor antibodies and uses thereof
TWI868050B (zh) * 2017-05-05 2025-01-01 美商安進公司 用於改良儲存及投與之包含雙特異性抗體構築體之醫藥組成物
SG11202101980VA (en) 2018-09-12 2021-03-30 Silverback Therapeutics Inc Methods and composition for the treatment of disease with immune stimulatory conjugates
KR102337683B1 (ko) 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
MX2021015533A (es) 2019-06-19 2022-02-10 Silverback Therapeutics Inc Anticuerpos anti-mesotelina e inmunoconjugados de los mismos.
BR112022007635A2 (pt) * 2019-11-13 2022-07-12 Pfizer Formulação aquosa e estável de anticorpos
WO2021168274A1 (en) 2020-02-21 2021-08-26 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
IL299508A (en) 2020-07-01 2023-02-01 Ars Pharmaceuticals Inc Anti-asgr1 antibody conjugates and uses thereof
AU2021324314A1 (en) 2020-08-12 2023-05-25 Innate Pharma Subcutaneous anti-c5ar antagonist treatment regimen with avdoralimab
EP4216923A1 (en) * 2020-09-24 2023-08-02 Novo Nordisk Health Care AG Pharmaceutical formulation of concizumab and method of production thereof
CN112244025A (zh) * 2020-11-27 2021-01-22 上海创宏生物科技有限公司 大分子蛋白和/或核酸用无菌处理剂及其制备方法和应用
AU2023367497A1 (en) * 2022-10-26 2025-05-15 Nihon Medi-Physics Co., Ltd. Radioactive pharmaceutical composition
TW202508625A (zh) * 2023-05-01 2025-03-01 美商再生元醫藥公司 使用苯酚或苯甲醇之多劑量抗體藥物產品

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US20020099179A1 (en) 1989-12-21 2002-07-25 Linda K. Jolliffe Cdr-grafted antibodies
DK261490D0 (da) 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
US6165467A (en) 1991-07-20 2000-12-26 Yoshihide Hagiwara Stabilized human monoclonal antibody preparation
US5789192A (en) 1992-12-10 1998-08-04 Schering Corporation Mammalian receptors for interleukin-10 (IL-10)
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
JP3681206B2 (ja) 1995-12-26 2005-08-10 株式会社三菱化学ヤトロン 抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
CN100502047C (zh) 1996-06-28 2009-06-17 精工爱普生株式会社 薄膜晶体管
EP0963377B1 (en) 1996-08-30 2009-03-04 Human Genome Sciences, Inc. Interleukin-19
US5985614A (en) 1996-08-30 1999-11-16 Human Genome Sciences, Inc. Polynucleotides encoding interleukin-19
US5945511A (en) 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
WO1998049198A1 (en) 1997-04-30 1998-11-05 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
AU8571198A (en) 1997-07-16 1999-02-10 Human Genome Sciences, Inc. Interleukin-20
US6486301B1 (en) 1997-07-16 2002-11-26 Human Genome Sciences, Inc. Interleukin-20
US6020163A (en) 1997-08-06 2000-02-01 Zymogenetics, Inc. Lipocalin homolog
US6576743B1 (en) 1997-11-26 2003-06-10 Zymogenetics, Inc. Mammalian cytokine-like polypeptide-10
JP4271850B2 (ja) 1998-01-23 2009-06-03 イミュネックス・コーポレーション Ｉｌ−１８受容体
AU2871899A (en) 1998-03-09 1999-09-27 Schering Corporation Human receptor proteins; related reagents and methods
PT1490386E (pt) 1998-03-10 2008-11-24 Genentech Inc Novos polipéptidos e ácidos nucleicos que os codificam
US7198789B2 (en) 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
CN1233476A (zh) 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
WO1999061630A2 (en) 1998-05-26 1999-12-02 Regeneron Pharmaceuticals, Inc. Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system
WO1999062934A1 (en) 1998-06-05 1999-12-09 Human Genome Sciences, Inc. Interferon receptor hkaef92
US7041805B2 (en) 1998-09-01 2006-05-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1113799A4 (en) * 1998-09-17 2004-06-09 Lilly Co Eli PROTEIN-BASED PREPARATION
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
US6451286B1 (en) * 1998-12-21 2002-09-17 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
AU2222700A (en) 1998-12-31 2000-07-31 Millennium Pharmaceuticals, Inc. Class ii cytokine receptor-like proteins and nucleic acids encoding them
AU3774300A (en) 1999-06-02 2000-12-18 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20050060101A1 (en) 1999-06-28 2005-03-17 Bevilacqua Michael P. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
IL149008A0 (en) 1999-10-04 2002-11-10 Chiron Corp Stabilized liquid polypeptide-containing pharmaceutical compositions
KR100399156B1 (ko) * 1999-11-19 2003-09-26 주식회사 엘지생명과학 α-인터페론의 용액제형
JP4741139B2 (ja) 1999-12-23 2011-08-03 ザイモジェネティクス， インコーポレイテッド 可溶性インターロイキン−２０レセプター
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
IL152130A0 (en) 2000-04-07 2003-05-29 Ellis L Kline Methods and compositions for treating neoplasms
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
EP1336410A4 (en) 2000-08-04 2005-10-12 Chugai Pharmaceutical Co Ltd PROTEIN INJECTION PREPARATIONS
EP1337636B1 (en) 2000-08-08 2006-10-18 ZymoGenetics, Inc. Soluble zcytor 11 cytokine receptors
DK1314437T3 (da) 2000-08-11 2014-07-14 Chugai Pharmaceutical Co Ltd Stabiliserede antistofindeholdende præparater
IL155002A0 (en) 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
WO2002070001A2 (en) 2001-02-28 2002-09-12 Eli Lilly And Company Use of lp82 to treat hematopoietic disorders
DE60232511D1 (de) 2001-03-09 2009-07-16 Zymogenetics Inc Löslicher heterodimerer cytokinrezeptor
CA2454587C (en) * 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
DK1432431T3 (en) 2001-10-04 2017-07-10 Genetics Inst Llc Methods and compositions for modulating interleukin-21 activity
US7022289B1 (en) 2001-10-10 2006-04-04 The United States Of America As Represented By The Secretary Of The Army Chemical and biological sampling device and kit and method of use thereof
PT2308888T (pt) * 2001-11-14 2017-05-03 Janssen Biotech Inc Anticorpos anti-il-6, composições, métodos e utilizações
WO2003051384A1 (en) 2001-12-17 2003-06-26 Zymogenetics, Inc. Method for treating cervical cancer
MXPA04007924A (es) 2002-02-14 2005-05-17 Chugai Pharmaceutical Co Ltd Formulaciones en solucion que contienen anticuerpo.
DK1478394T3 (da) 2002-02-27 2008-10-13 Immunex Corp Stabiliseret TNFR-Fc formulation med arginin
US20050063947A1 (en) 2002-03-27 2005-03-24 Patrick Hwu Method for treating cancer in humans
US20040009168A1 (en) 2002-04-05 2004-01-15 Elizabet Kaisheva Multidose antibody formulation
EP2377547A1 (en) 2002-06-07 2011-10-19 ZymoGenetics, Inc. Use of IL-21 as an antimicrobial agent
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040022792A1 (en) 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
WO2004001007A2 (en) 2002-06-21 2003-12-31 Idec Pharmaceuticals Corporation Buffered formulations for concentrating antibodies and methods of use thereof
WO2004009479A1 (en) 2002-07-18 2004-01-29 Fabio Perini S.P.A. Storage unit for elongated products
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US20040191243A1 (en) * 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
RU2358763C2 (ru) 2003-02-10 2009-06-20 Элан Фармасьютикалз, Инк. Композиции иммуноглобулина и способ их получения
DK2335725T3 (en) 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
UA115960C2 (uk) 2003-07-15 2018-01-25 Емджен, Інк., Людські анти-ngf нейтралізуючі антитіла як селективні інгібітори метаболічних шляхів фактора росту нервової тканини (ngf)
EP1698640B2 (en) 2003-10-01 2019-06-19 Kyowa Hakko Kirin Co., Ltd. Method of stabilizing antibody and stabilized solution-type antibody preparation
US20070184050A1 (en) 2003-12-25 2007-08-09 Kirin Beer Kabushiki Kaisha Stable water-based medicinal preparation containing antibody
EP1755677A4 (en) 2004-06-14 2009-11-25 Medimmune Vaccines Inc HIGH-PRESSURE SPRAY DRYING OF BIOACTIVE MATERIALS
BRPI0516975A (pt) 2004-10-22 2008-09-30 Zymogenetics Inc anticorpo ou seu fragmento de ligação a antìgeno, composição farmacêutica, imunoconjugado, hibridoma, anticorpo monoclonal, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno
WO2006086396A2 (en) 2005-02-08 2006-08-17 Zymogenetics, Inc. Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
US7525604B2 (en) 2005-03-15 2009-04-28 Naxellent, Llc Windows with electrically controllable transmission and reflection
EP2264162A1 (en) 2005-07-02 2010-12-22 Arecor Limited Stable aqueous systems comprising proteins
WO2007006858A2 (en) 2005-07-12 2007-01-18 Oy Jurilab Ltd Method for treatment of cardiovascular and metabolic diseases and detecting the risk of the same
EP1916997B1 (en) 2005-08-05 2018-04-18 Amgen Inc. Stable aqueous protein pharmaceutical formulations and their preparation
AU2006294477A1 (en) 2005-09-27 2007-04-05 Source Mdx Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
WO2007038501A2 (en) 2005-09-27 2007-04-05 The Feinstein Institute For Medical Research Rheumatoid arthritis markers
EP1951865A4 (en) 2005-11-21 2010-06-23 Sanofi Pasteur Ltd STABILIZING FORMULATIONS FOR RECOMBINANT VIRUSES
CN101378782A (zh) 2005-12-21 2009-03-04 惠氏公司 粘度降低的蛋白质制剂及其用途
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
US20080071063A1 (en) 2006-02-03 2008-03-20 Medimmune, Inc. Protein Formulations
DE102006005094A1 (de) 2006-02-04 2007-08-09 Degussa Gmbh Titandioxid und Polycarboxylatether enthaltende Dispersion
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
WO2007105133A2 (en) 2006-03-15 2007-09-20 Koninklijke Philips Electronics N.V. Remote control pointing technology with roll detection
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
US8048421B2 (en) 2006-03-23 2011-11-01 Kyowa Hakko Kirin Co., Ltd. Agonist antibody to human thrombopoietin receptor
AU2007229554A1 (en) * 2006-03-28 2007-10-04 F. Hoffmann-La Roche Ag Anti-IGF-1R human monoclonal antibody formulation
EP1857559A1 (en) 2006-05-16 2007-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for predicting responsiveness to TNF alpha blocking agents
MX2008015852A (es) 2006-06-14 2009-02-23 Imclone Systems Inc Formulaciones liofilizadas de anticuerpos anti-egfr.
CN101472611A (zh) 2006-06-19 2009-07-01 惠氏公司 调节il-22和il-17的方法
MX2008015830A (es) 2006-06-30 2009-01-09 Novo Nordisk As Anticuerpos anti-nkg2a y usos de los mismos.
US20080112953A1 (en) 2006-10-06 2008-05-15 Amgen Inc. Stable formulations
RU2009111138A (ru) 2006-10-12 2010-11-20 Вайет (Us) Способы и композиции с уменьшенной опалесценцией
WO2008048986A2 (en) 2006-10-17 2008-04-24 Children's Hospital Medical Center Gene array technique for predicting response in inflammatory bowel diseases
CA2668955A1 (en) 2006-11-09 2008-05-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for predicting therapeutic responsiveness to tnf-alpha blocking agents
CA2671968A1 (en) 2006-12-11 2008-06-19 F. Hoffmann-La Roche Ag Abeta antibody parenteral formulation
CL2008000058A1 (es) * 2007-01-09 2008-05-23 Wyeth Corp Formulacion que comprende un anticuerpo anti-il13, un criprotector, y una solucion amortiguadora; composicion farmaceutica que la comprende; metodo para tratar un trastorno relacionado con il13; y formas farmaceuticas que la comprenden.
EP2132343B1 (en) 2007-03-01 2012-08-29 Université Catholique de Louvain Method for the determination and the classification of rheumatic conditions
JP5152177B2 (ja) 2007-03-23 2013-02-27 パナソニック株式会社 導電性バンプとその製造方法および電子部品実装構造体
WO2008121615A2 (en) 2007-03-30 2008-10-09 Medimmune, Inc. Antibody formulation
GB0707938D0 (en) 2007-04-25 2007-05-30 Univ Strathclyde Precipitation stabilising compositions
WO2008132176A2 (en) 2007-04-27 2008-11-06 Universite Catholique De Louvain Method for evaluating the response of an individual to tnf blocking therapy
US20100303813A1 (en) 2007-06-08 2010-12-02 Biogen Idec Ma Inc. Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
BRPI0814252B8 (pt) 2007-06-14 2021-05-25 Biogen Idec Inc composição farmacêutica aquosa estável compreendendo natalizumabe, dose unitária, e seringa pré-cheia
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
US20090004189A1 (en) 2007-06-18 2009-01-01 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
US7951368B2 (en) 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
US20100189721A1 (en) 2007-07-06 2010-07-29 Smithkline Beecham Corporation Antibody formulations
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
EP2174132A2 (en) 2007-07-20 2010-04-14 National Institute for Bioprocessing Research and Training Limited Glycosylation markers for cancer and chronic inflammation
WO2009015398A1 (en) 2007-07-26 2009-01-29 Oklahoma Medical Research Foundation Methods for inflammatory disease management
EP2225275A4 (en) 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
CA3102679A1 (en) 2007-12-14 2009-06-25 Birgitte Urso Antibodies against human nkg2d and uses thereof
CN101970494B (zh) 2008-02-20 2015-01-21 G2炎症私人有限公司 人源化抗-C5aR抗体
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
JP2011523408A (ja) 2008-05-15 2011-08-11 ノボ・ノルデイスク・エー／エス 抗体精製方法
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
JP2011526591A (ja) 2008-06-30 2011-10-13 ノボ・ノルデイスク・エー／エス 抗ヒトインターロイキン−２０抗体
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
US20110159011A1 (en) 2008-08-28 2011-06-30 Wyeth Llc Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases
PE20110302A1 (es) 2008-09-19 2011-05-21 Hoffmann La Roche Formulacion farmaceutica de un anticuerpo contra p-selectina
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
MX2011006501A (es) 2008-12-22 2011-07-12 Novo Nordisk As Anticuerpos contra inhibidor de la via de factor de tejido.
WO2010113096A1 (en) 2009-03-30 2010-10-07 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods of predicting clinical course and treating multiple sclerosis
MX2012002766A (es) 2009-09-03 2012-04-02 Genentech Inc Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
US8580528B2 (en) 2009-10-16 2013-11-12 Stichting Vu-Vumc Method for prognosticating the clinical response of a patient to B-lymphocyte inhibiting or depleting therapy
WO2011047073A2 (en) 2009-10-16 2011-04-21 Mayo Foundation For Medical Education And Research Assessing rheumatoid arthritis
BR112012021576A2 (pt) 2010-02-26 2016-10-25 Novo Nordisk As composições estáveis contendo anticorpo.
US20130136733A1 (en) * 2010-05-28 2013-05-30 Novo Nordisk A/S Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
EP2576824A2 (en) 2010-06-07 2013-04-10 Roche Diagnostics GmbH Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases

Similar Documents

Publication Publication Date Title
JP2013527189A5 (OSRAM)
RU2012153786A (ru) Стабильные многодозовые композиции, содержащие антитело и консервант
PE20190405A1 (es) FORMULACION PARA ANTICUERPO ANTI-alfa4beta7
JP2010522208A5 (OSRAM)
MY178654A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy
EA201000211A1 (ru) Способ модулирования рецептора gpr119, сопряженного с g-белком, и используемые при этом соединения
WO2010063011A3 (en) Methods for the treatment of infections and tumors
MA35156B1 (fr) 4-amino-5-fluoro-3-[6-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinoléin-2-one destinée à être utilisée dans le traitement du carcinome adénoïde kystique
PE20170948A1 (es) Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r)
WO2014066468A8 (en) Stable, low viscosity antibody formulation
NZ702801A (en) Treatment of sanfilippo syndrome type b
MY160074A (en) Protopanaxadiol-type ginsenoside compositions and uses thereof
EP2773671A4 (en) DESIGN OF STABLE HETERODIMERIC ANTIBODIES WITH MUTATIONS IN FC DOMAIN
WO2008083174A3 (en) Compositions and methods for the treatment of infections and tumors
EA201792541A3 (ru) Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
BR112014031310A2 (pt) anticorpos anti-pcsk9, formulações, dosagem e métodos de uso
EA200970274A1 (ru) Способы введения гипогликемических средств с длительным действием
CO6220900A2 (es) Forma dosificadora novedosa
EA201391339A1 (ru) Применение антагонистов рецептора аденозина aдля лечения сердечной недостаточности и аритмии у пациентов после инфаркта миокарда
JP2016534062A5 (OSRAM)
WO2009132082A3 (en) Immunogenic compositions containing ceramide and methods of use thereof
RU2012107483A (ru) Отамиксабан для лечения инфаркта миокарда без подъема сегмента st у пациентов пожилого возраста и пациентов с нарушенной функцией почек
BR112013027685A2 (pt) composição oral líquida compreendendo divalproex sódico e processo de preparação do mesmo
EA201391827A1 (ru) Соединения [1,2,4]тиадиазин 1,1-диоксида для снижения мочевой кислоты в сыворотке
WO2010019565A3 (en) Anti-ephrin b2 antibodies and their use in treatment of disease